Efficacy and Safety of Acitretin Plus Pioglitazone in Patients With Psoriasis

• Status: Completed
• Trial end date: 2008-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Acitretin, when given in combiantion with pioglitazone might achieve better and/or more rapid control of moderate to severe chronic plaque type psoriasis.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Postgraduate Institute of Medical Education and Research
• Treatments: Acitretin; Pioglitazone

Criteria

Inclusion Criteria:

• Patients with chronic plaque type psoriasis having body surface area involvement of > 20%

• Patients of either sex

• Females who have completed their family and are tubectomized or are postmenopausal i.e. no menstrual bleeding over at least 1 year

• Age range 18-65 years

Exclusion Criteria:

• Females of child bearing potential

• H/O hypersensitivity to acitretin

• Impaired hepatic function (serum bilirubin, AST, ALT and alkaline phosphatase >1.5 times the upper limit of normal)

• Impaired renal function (serum creatinine >1.5mg% in males and >1.4 mg% in females)

• Hyperlipidemia

• BMI >30 kg /m2

• H/O excessive alcohol use

• Diabetes mellitus

• Congestive heart failure

• Ischemic heart disease